FDA Process Validation

FDA Process Validation refers to the FDA's January 2011 guidance document "Process Validation: General Principles and Practices" (issued by CDER in cooperation with CBER, ORA, and CVM, superseding the agency's 1987 process-validation guideline), and to the three-stage lifecycle framework it establishes for demonstrating that a pharmaceutical or biologic manufacturing process consistently produces a product meeting its predetermined quality attributes. A manufacturing process is treated as "validated" under this framework only when all three stages have been satisfied: Stage 1 (Process Design), in which the commercial process is defined based on knowledge gained through development and scale-up activities; Stage 2 (Process Qualification), in which the process design is evaluated to confirm the process is capable of reproducible commercial manufacturing, including facility/utility/equipment qualification and Process Performance Qualification (PPQ) runs; and Stage 3 (Continued Process Verification, or CPV), an ongoing program of collecting and statistically trending process and product data during routine commercial production to confirm the process remains in a state of control. This is distinct from clinical-trial protocol validation or software/computer-system validation -- the term specifically denotes manufacturing-process validation for drug substances, drug products, and biologics under current Good Manufacturing Practice (CGMP).

ByCASRAI Editorial Board

· Last updated 18 Jul 2026

Worked examples

Is an instance

A sponsor preparing a Biologics License Application (BLA) documents Stage 1 process-design studies (small-scale and pilot-scale characterization work identifying critical process parameters), then executes Stage 2 Process Performance Qualification -- typically a small number of full-scale commercial batches manufactured under the finalized process and sampled extensively -- before the process is considered qualified for routine commercial manufacturing; ongoing Stage 3 monitoring then continues for the life of the product.

Is an instance

A generic-drug manufacturer preparing an Abbreviated New Drug Application (ANDA) structures its validation master plan around the same three FDA stages even though the product itself relies on bioequivalence rather than de novo clinical data -- the manufacturing-process validation expectations under the 2011 guidance and 21 CFR Part 211 apply independently of how safety and efficacy were established.

Looks similar, but isn't

Not an instance

Validating that a clinical trial's data-collection instrument or case report form accurately captures the intended endpoints is protocol/instrument validation, not FDA Process Validation -- the 2011 guidance is a CGMP manufacturing framework and does not govern clinical-trial design or measurement validity.

Not an instance

A single successful Process Performance Qualification run, by itself, is not "process validation" complete -- it satisfies part of Stage 2 only. The framework requires an ongoing Stage 3 Continued Process Verification program for the process to remain validated throughout commercial production, not just a point-in-time qualification event.

“FDA Process Validation” refers both to a specific FDA guidance document and to the three-stage lifecycle approach it defines for validating pharmaceutical and biologic manufacturing processes.

The 2011 guidance document

FDA’s Center for Drug Evaluation and Research (CDER), in cooperation with the Center for Biologics Evaluation and Research (CBER), the Office of Regulatory Affairs (ORA), and the Center for Veterinary Medicine (CVM), issued “Process Validation: General Principles and Practices” in January 2011, superseding the agency’s earlier 1987 process-validation guideline. The 2011 guidance shifted FDA’s expectations away from a narrow, one-time “three validation batches and done” model toward a lifecycle approach explicitly aligned with the CGMP regulations in 21 CFR Parts 210 and 211 and with contemporary quality-system thinking (the guidance was developed with awareness of ICH Q8, Q9, and Q10 concepts, though it is an FDA document rather than an ICH-harmonized one).

The three-stage lifecycle

The guidance organizes process validation into three connected stages that together span a product’s entire manufacturing life cycle rather than a single qualification event:

Stage 1: Process Design

The commercial manufacturing process is defined based on knowledge gained through development, scale-up, and technology-transfer activities. This stage identifies critical process parameters (CPPs) and critical quality attributes (CQAs) and establishes the design space and control strategy the later stages will confirm.

Stage 2: Process Qualification

The process design from Stage 1 is evaluated to confirm it is capable of reproducible commercial manufacturing. This stage has two elements: qualification of the facility, utilities, and equipment involved, and Process Performance Qualification (PPQ) — execution of the process design, typically across a defined number of full-scale commercial batches manufactured under actual or simulated commercial conditions, with heightened sampling and monitoring to confirm the process performs as intended. A successful PPQ demonstrates the process is capable; it does not, by itself, constitute a validated process for the life of the product.

Stage 3: Continued Process Verification (CPV)

An ongoing program of collecting and statistically trending process and product data throughout routine commercial production to confirm the process remains in a state of control. CPV connects directly to the CGMP requirement at 21 CFR 211.180(e) for an ongoing program of data review, and continues for as long as the product is manufactured. See CASRAI’s Continued Process Verification (CPV) entry for a detailed treatment of Stage 3 specifically.

Why the distinction from clinical-trial validation matters

Research administrators and regulatory-affairs staff working across both clinical and manufacturing/CMC (chemistry, manufacturing, and controls) functions can encounter “validation” used in several distinct senses. FDA Process Validation, as described above, is a CGMP manufacturing-quality concept governing whether a drug substance, drug product, or biologic manufacturing process reliably produces product meeting its specifications. It is unrelated to protocol validation, instrument/questionnaire validation, or computer-system validation (CSV) in a clinical-trial context — those concern the integrity of clinical data collection and trial conduct, not the manufacturing process that produced the investigational or commercial product itself. Organizations running both drug-development and manufacturing functions should keep these usages clearly separated in SOPs and validation master plans.

Related concepts

Continued Process Verification (CPV) — Stage 3 of this framework, treated in its own entry.
Good Laboratory Practice (GLP) — the related nonclinical-research quality standard.
Inspection Readiness — CGMP inspection preparedness, which process-validation documentation directly supports.

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="FDA Process Validation"
      vocab-term-identifier="https://casrai.org/dictionary/term/fda-process-validation" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/fda-process-validation",
  "name": "FDA Process Validation",
  "identifier": "https://casrai.org/dictionary/term/fda-process-validation",
  "description": "FDA Process Validation refers to the FDA's January 2011 guidance document \"Process Validation: General Principles and Practices\" (issued by CDER in cooperation with CBER, ORA, and CVM, superseding the agency's 1987 process-validation guideline), and to the three-stage lifecycle framework it establishes for demonstrating that a pharmaceutical or biologic manufacturing process consistently produces a product meeting its predetermined quality attributes. A manufacturing process is treated as \"validated\" under this framework only when all three stages have been satisfied: Stage 1 (Process Design), in which the commercial process is defined based on knowledge gained through development and scale-up activities; Stage 2 (Process Qualification), in which the process design is evaluated to confirm the process is capable of reproducible commercial manufacturing, including facility/utility/equipment qualification and Process Performance Qualification (PPQ) runs; and Stage 3 (Continued Process Verification, or CPV), an ongoing program of collecting and statistically trending process and product data during routine commercial production to confirm the process remains in a state of control. This is distinct from clinical-trial protocol validation or software/computer-system validation -- the term specifically denotes manufacturing-process validation for drug substances, drug products, and biologics under current Good Manufacturing Practice (CGMP).",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
  "url": "https://casrai.org/dictionary/term/fda-process-validation",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-18T06:30:46",
  "inLanguage": "en"
}